Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.

Robert T NaismithRobert A BermelChristopher S CoffeyAndrew D GoodmanJanel FedlerMarianne KearneyEric C KlawiterKunio NakamuraSridar NarayananChristopher GoebelJon YankeyElizabeth KlingnerRobert J Foxnull null

Published in: Neurology (2020)

This study provides Class II evidence that for people with MS, ibudilast does not significantly reduce new or enlarging T2 lesions or new T1 lesions.

Keyphrases

mass spectrometry
multiple sclerosis
computed tomography
contrast enhanced
body composition